Klivira
Request demo

Optimizing Rexulti Prior Authorization for Rheumatology Patients

Managing Rexulti prior authorization for rheumatology patients adds complexity to an already high-burden specialty. Klivira automates the PA process to ensure timely access for essential medications.

Revenue cycle directors and prior authorization coordinators in rheumatology clinics face significant challenges with medication PAs. While rheumatology primarily focuses on biologics and targeted DMARDs, patients with chronic conditions often require medications like Rexulti for comorbid mental health issues, each presenting its own distinct prior authorization requirements and workflow hurdles.

The Nuance of Rexulti Prior Authorization in Rheumatology Settings

Rexulti (brexpiprazole) is an atypical antipsychotic, not a direct treatment for rheumatic diseases. However, patients with chronic rheumatic conditions frequently experience comorbid mental health conditions requiring medications like Rexulti. Managing prior authorization for such essential, co-managed medications becomes an integral part of the overall administrative burden for rheumatology practices, demanding efficient and precise PA workflows.

Navigating High-Volume Prior Authorizations in Rheumatology

Rheumatology is among the highest-PA-burden specialties due to the chronic nature of the diseases and the high cost of advanced agents. Prior authorization concentrates heavily in categories like biologics (e.g., Humira, Enbrel, Stelara, Skyrizi, Rinvoq), JAK inhibitors, and infusion therapy. This existing complexity means that managing additional PAs for comorbid conditions, such as those requiring Rexulti, further strains clinic resources.

Essential Documentation for Medications in Rheumatology Care

  • Diagnosis documentation for both the primary rheumatic condition (e.g., RA: 2010 ACR/EULAR criteria) and any comorbid conditions justifying medications like Rexulti.
  • Detailed medical necessity and rationale for the prescribed medication, including its place in the line of therapy.
  • Completion of relevant screenings (e.g., TB, hepatitis B/C for immunosuppressants) or general health assessments.
  • Documentation of prior conventional DMARD trials (for rheumatic drugs) or prior medication trials (step therapy) for comorbid conditions.
  • Disease activity assessments (e.g., DAS28, CDAI for RA) for rheumatic agents, and relevant clinical scales for comorbid mental health conditions.
  • Compliance with payer-specific step therapy requirements, applicable to the specific drug's class.

Common Prior Authorization Denial Reasons Impacting Rheumatology Practices

  • Insufficient documentation of medical necessity or diagnosis for the prescribed agent.
  • Failure to document completion of required step therapy for the specific drug class, whether for a biologic or a psychiatric medication.
  • Missing or incomplete screening results or other prerequisite documentation.
  • Lack of documented disease activity or response criteria, particularly for rheumatic drugs.
  • Off-label use without specific payer policy support for the requested indication.
  • Inconsistent application of biosimilar substitution policies for biologics, leading to brand denials.

Klivira's Comprehensive Approach to Prior Authorization Automation

Klivira's platform addresses the multifaceted challenges of prior authorization by integrating directly with EMRs and payer portals. Our system streamlines PA for both high-cost biologics and medications like Rexulti for comorbid conditions, reducing administrative burden and accelerating patient access. We apply ACR-guideline-aware policy logic where applicable, manage biosimilar substitution routing, and facilitate periodic re-authorization workflows for chronic treatments.

Frequently asked questions

How does Klivira handle prior authorizations for medications like Rexulti that aren't direct treatments for rheumatic diseases but are prescribed to rheumatology patients?

Klivira's platform is designed to manage prior authorizations for all medications a clinic prescribes, regardless of whether they directly treat the primary specialty's conditions. For drugs like Rexulti, we integrate with EMRs to extract documentation for comorbid conditions and apply payer-specific policy logic to streamline the approval process, ensuring comprehensive PA management within the rheumatology patient's overall care plan.

What specific documentation is required for Rexulti prior authorization in a rheumatology setting?

While ACR guidelines don't apply to Rexulti, payers will require documentation of the comorbid mental health diagnosis (e.g., major depressive disorder, schizophrenia), a clear demonstration of medical necessity for Rexulti, and often a history of prior medication trials (step therapy) for that specific condition. Klivira helps aggregate this diverse documentation efficiently from your EMR.

How does Klivira manage the different PA requirements for pharmacy benefit vs. medical benefit drugs, especially when a rheumatology patient might be on both?

Klivira's system intelligently routes prior authorization requests based on the benefit type (pharmacy or medical) and payer policy. This ensures that whether a drug like Rexulti falls under pharmacy benefit (NCPDP SCRIPT ePA) or a biologic under medical benefit (X12 278), the correct pathway is followed, standardizing the process across all medication types for a rheumatology patient.

Can Klivira help with re-authorizations for chronic medications in rheumatology, including those for comorbid conditions?

Yes, Klivira supports periodic re-authorization workflows for all chronic treatments. Our platform tracks re-authorization timelines and proactively prompts for necessary updated documentation, such as continued medical necessity or disease response, ensuring continuous patient access to both rheumatic medications and those for comorbid conditions without lapses.

How does Klivira address payer-specific variations for drugs prescribed in rheumatology, including those for comorbid conditions?

Klivira maintains a comprehensive, continuously updated library of payer policies. Our system applies these specific rules, including step therapy requirements, biosimilar mandates, and documentation nuances, ensuring each PA request for any drug, from biologics to Rexulti, is compliant with the individual payer's criteria and reducing the risk of denials due to policy discrepancies.

Related coverage

Other rexulti prior authorization by payer

Other rexulti prior authorization by specialty

Ready to automate prior auth for this drug?

See how Klivira automates prior authorizations for your team.

Request a demo